Rational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions.

Article Details

Citation

Zhou Q, Yan XF, Zhang ZM, Pan WS, Zeng S

Rational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions.

World J Gastroenterol. 2007 Nov 14;13(42):5618-28.

PubMed ID
17948937 [ View in PubMed
]
Abstract

AIM: To review and summarize drug metabolism and its related interactions in prescribing drugs within the similar therapeutic or structural class for gastrointestinal disease treatment so as to promote rational use of medicines in clinical practice. METHODS: Relevant literature was identified by performing MEDLINE/Pubmed searches covering the period from 1988 to 2006. RESULTS: Seven classes of drugs were chosen, including gastric proton pump inhibitors, histamine H(2)-receptor antagonists, benzamide-type gastroprokinetic agents, selective 5-HT(3) receptor antagonists, fluoroquinolones, macrolide antibiotics and azole antifungals. They showed significant differences in metabolic profile (i.e., the fraction of drug metabolized by cytochrome P450 (CYP), CYP reaction phenotype, impact of CYP genotype on interindividual pharmacokinetics variability and CYP-mediated drug-drug interaction potential). Many events of severe adverse drug reactions and treatment failures were closely related to the ignorance of the above issues. CONCLUSION: Clinicians should acquaint themselves with what kind of drug has less interpatient variability in clearance and whether to perform CYP genotyping prior to initiation of therapy. The relevant CYP knowledge helps clinicians to enhance the management of patients with gastrointestinal disease who may require treatment with polytherapeutic regimens.

DrugBank Data that Cites this Article

Drug Enzymes
DrugEnzymeKindOrganismPharmacological ActionActions
DihydroergotamineCytochrome P450 3A4ProteinHumans
Unknown
Substrate
Inhibitor
Details
ErgometrineCytochrome P450 3A4ProteinHumans
Unknown
Substrate
Details
OfloxacinCytochrome P450 1A2ProteinHumans
Unknown
Inhibitor
Details
RanitidineCytochrome P450 1A2ProteinHumans
Unknown
Substrate
Inhibitor
Details
Drug Interactions
DrugsInteraction
Acenocoumarol
Caffeine
The metabolism of Acenocoumarol can be decreased when combined with Caffeine.
Acenocoumarol
Alosetron
The metabolism of Acenocoumarol can be decreased when combined with Alosetron.
Acenocoumarol
Lidocaine
The metabolism of Acenocoumarol can be decreased when combined with Lidocaine.
Acenocoumarol
Mexiletine
The metabolism of Acenocoumarol can be decreased when combined with Mexiletine.
Acenocoumarol
Tocainide
The metabolism of Acenocoumarol can be decreased when combined with Tocainide.